Clinical Trial Update: Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Lotemax Gel 0.5% and Restasis 0.05% in participants with mild or moderate keratoconjunctivitis sicca (dry eye disease) has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• Lotemax Gel 0.5% (loteprednol etabonate)
• Restasis 0.05% (cyclosporine ophthalmic emulsion)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Keratoconjunctivitis Sicca | Phase 2 | Status: COMPLETED | Results posted: 2019-08-30